pipette
ESEspañol

Longitudinal remodeling of the tumor-immune microenvironment during regorafenib, nivolumab, and chemotherapy in advanced gastric cancer

Kota Itahashi, Akihito Kawazoe, Tadayoshi Hashimoto, Yue Yan, Takuma Irie, 小野宏美, Hitomi Tamura, Kyoko Hongo, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Yoshiaki Nakamura, Takao Fujisawa, Tomohiro Iwasawa, Tomoya Suzuki, Izuma Nakayama, Yasuhiro Kojima, Takayuki Yoshino, Hiroyoshi Nishikawa, Shohei Koyama, Kohei Shitara

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells.

Appeared: Friday, November 6. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aec7235